JSR Pursues New Developments in Life Sciences Business

摘要

JSR Corp. (TYO:4185) is stepping up its efforts to develop new business in the company’s Life Sciences Corp. As one part of this, JSR will look to accelerate growth by boosting capacity for its biopharma contract development and manufacturing organization (CDMO) and contract research organization (CRO) operations. Then in addition, materials for manufacturing use are similarly anticipated to enter a period of rapid expansion to the tune of 35 percent annual growth through new projects.